Ongoing investigations into the drug are demonstrating promising outcomes regarding body composition . Initially created for treating type 2 diabetes , this GLP-1 receptor agonist has indicated https://socialicus.com/story6986467/semaglutide-research-revealing-new-body-reduction-opportunities